# Hologic **Source:** https://geo.sig.ai/brands/hologic **Vertical:** Healthcare Tech **Subcategory:** Enterprise **Tier:** Leader **Website:** hologic.com **Last Updated:** 2026-04-14 ## Summary Women's health medtech with $3.9B FY2024 revenue; 3D Genius Mammography market leader; Panther molecular diagnostics platform; annual screening guidelines expand mammography TAM by ~30%. ## Company Overview Hologic is a global medical technology company uniquely dedicated to women's health, founded in 1985 and headquartered in Marlborough, Massachusetts, trading on Nasdaq (HOLX). The company generated approximately $3.9 billion in revenues for fiscal year 2024 (ending September 28) under CEO Stephen MacMillan, who has led Hologic since 2013 and transformed it from a single-product mammography company into a diversified women's health platform. Hologic's four business segments serve distinct clinical needs: Diagnostics (Panther molecular testing platform, cervical health testing, and COVID-19 diagnostics), Breast Health (3D mammography, breast biopsy guidance systems, radiation therapy), Surgical (NovaSure endometrial ablation, MyoSure fibroid removal, and minimally invasive hysteroscopy), and Skeletal Health (bone density measurement). The 3D Genius Mammography system—based on tomosynthesis technology that creates a 3D X-ray view of breast tissue, dramatically improving cancer detection versus traditional 2D mammography—is Hologic's foundational product and the standard of care for breast cancer screening at the majority of U.S. mammography facilities. The Panther system, inherited through Hologic's 2012 acquisition of Gen-Probe for $3.7 billion, is the leading fully automated molecular diagnostics platform for sexually transmitted infections (chlamydia, gonorrhea, trichomonas, HPV), enabling high-throughput testing in clinical labs. The COVID pandemic temporarily transformed Hologic into a major diagnostics company as Panther's throughput capacity enabled COVID-19 molecular test production, generating $1+ billion in quarterly COVID test revenues in 2021-2022 before declining to baseline. In 2025-2026, Hologic navigates the post-COVID revenue normalization while reinvesting COVID windfall profits into acquisitions and R&D that expand the women's health platform. Acquisitions of Bolder Surgical (2021), Mobidiag (molecular diagnostics), and Acessa Health (laparoscopic fibroid treatment) have expanded the minimally invasive surgical portfolio and international diagnostics presence. The Breast Health business benefits from expanded mammography screening guidelines recommending annual screening beginning at age 40 (updated American Cancer Society and USPSTF guidance), which increases the addressable screening population by approximately 30%. Competitors include Becton Dickinson (molecular diagnostics), Siemens Healthineers and GE HealthCare (imaging), and Cooper Surgical (minimally invasive gynecological procedures). ## Frequently Asked Questions ### What does Hologic do? Hologic is a medical technology company primarily focused on improving women's health through early detection and treatment solutions. The company develops, manufactures, and supplies diagnostic products, medical imaging systems, and surgical devices across four business segments: Diagnostics (molecular diagnostics, cervical cancer screening), Breast Health (3D mammography, AI-enhanced imaging, biopsy systems), GYN Surgical (endometrial ablation, fibroid treatment), and Skeletal Health (bone densitometry for osteoporosis). Hologic's technologies are used by healthcare providers in over 36 countries to screen, diagnose, and treat conditions affecting women's health. ### Who are Hologic's customers and target markets? Hologic's primary customers are healthcare providers including hospitals, imaging centers, clinical laboratories, obstetrics and gynecology practices, radiology groups, and public health organizations. The company serves the women's health market globally, with products addressing breast cancer screening and diagnosis, cervical cancer screening, gynecological surgical procedures, and osteoporosis assessment. While Hologic focuses predominantly on women's health, its bone densitometry systems and some diagnostic products serve broader patient populations. The company's technologies impacted more than 193 million lives worldwide in 2024, demonstrating the global reach of its customer base. ### When was Hologic founded? Hologic was founded in 1985 by Dr. Jay A. Stein and S. David Ellenbogen in Bedford, Massachusetts with 12 employees and a mission to develop X-ray bone densitometry systems for osteoporosis diagnosis. The company went public in 1990, listing on the NASDAQ stock exchange under the ticker symbol HOLX. Over nearly four decades, Hologic has evolved from a specialized bone densitometry company into a comprehensive women's health technology leader through strategic acquisitions including Cytyc (2007), Third Wave Technologies (2008), and Gen-Probe (2012). ### Where is Hologic headquartered? Hologic is headquartered in Marlborough, Massachusetts, United States. The company maintains a global presence with operations in over 36 countries and approximately 7,000 employees worldwide. Hologic operates manufacturing facilities in multiple U.S. states including Wisconsin, Maine, and California, as well as international locations in countries such as Costa Rica, Belgium, and China. The company's global footprint enables it to serve healthcare providers and patients across North America, Europe, Asia-Pacific, and other international markets. ### What makes Hologic different from its competitors? Hologic differentiates itself through its singular focus on women's health, offering the most comprehensive portfolio of diagnostic and surgical solutions specifically designed for conditions affecting women. The company's Genius 3D Mammography technology detects 20-65% more invasive breast cancers than conventional 2D systems, while its ThinPrep Pap test is the world's most widely used cervical cancer screening method. Hologic has ranked #1 for Mammography System Performance and Customer Satisfaction for 11 consecutive years. The company's integration of artificial intelligence into diagnostic imaging through Genius AI Detection represents cutting-edge innovation in medical technology. Additionally, Hologic's workplace culture with 90% employee satisfaction and 97th percentile engagement rankings translates to superior product quality and customer service. ### Who are Hologic's main competitors? Hologic competes with various companies across its business segments. In breast imaging, primary competitors include GE Healthcare, Siemens Healthineers, and Fujifilm Medical Systems. In molecular diagnostics, the company competes with Roche Diagnostics, Abbott Laboratories, Becton Dickinson, and Qiagen. In gynecological surgical products, competitors include Boston Scientific, Medtronic, and CooperSurgical. In bone densitometry, DMS Imaging and Norland are key competitors. Hologic's focused strategy on women's health differentiates it from larger, more diversified medical device conglomerates that compete across broader healthcare markets. The company's market leadership positions in 3D mammography and cervical cancer screening provide competitive advantages in its core segments. ### How much funding has Hologic raised? Hologic went public in 1990 and has been a publicly traded company on the NASDAQ (ticker: HOLX) for over three decades, raising capital through its IPO and subsequent equity offerings. Rather than venture capital funding, Hologic's growth has been financed through public market capital, debt financing, and strong cash flow generation from operations. In October 2025, private equity firms Blackstone and TPG announced an agreement to acquire Hologic for $18.3 billion including debt, which would take the company private. This represents one of the largest medical device take-private transactions and reflects significant investor confidence in Hologic's market position and growth prospects. ### What is Hologic's market position in medical technology? Hologic holds market-leading positions in several women's health technology segments. The company is the global leader in 3D mammography with its Genius platform, holding the #1 ranking for Mammography System Performance and Customer Satisfaction for 11 consecutive years. The ThinPrep Pap test is the world's most widely used cervical cancer screening method. With fiscal 2024 revenue of $4.03 billion and a market capitalization of approximately $16.68 billion (prior to the announced take-private transaction), Hologic ranks among the top pure-play women's health medical technology companies globally. The company's technologies impacted 193 million lives in 2024, demonstrating the broad reach of its market presence. ### How can I contact Hologic? Healthcare providers and customers can contact Hologic through the company's website at www.hologic.com, which provides product information, technical support, and contact details for regional offices. For corporate inquiries, investor relations, or media requests, contact Hologic's headquarters in Marlborough, Massachusetts. The company maintains customer support operations in over 36 countries, with regional offices and service centers providing local language support and technical assistance. Product-specific inquiries can be directed to the appropriate business segment: Breast Health, Diagnostics, GYN Surgical, or Skeletal Health through the company directory available on the website. ### Is Hologic hiring? Yes, Hologic regularly hires for positions across its global workforce of approximately 7,000 employees. Career opportunities exist in research and development, manufacturing, clinical affairs, regulatory affairs, sales and marketing, customer service, and corporate functions. As a Great Place to Work-certified employer with 90% employee satisfaction ratings and recognition as a Top Workplace by Forbes and Fortune, Hologic offers competitive compensation, comprehensive benefits including mental health support through Lyra Health, wellness programs, leadership development opportunities, and the chance to work on technologies that impact millions of women's lives globally. Visit the careers section of hologic.com to explore current openings. ### What are Hologic's main products? Hologic's main products include: (1) Genius 3D Mammography with AI Detection for breast cancer screening; (2) ThinPrep Pap test and Genius Digital Diagnostics System for cervical cancer screening; (3) Molecular diagnostic systems for HPV testing and infectious disease diagnostics; (4) ATEC and Multicare breast biopsy systems plus Magseed/Magtrace surgical guidance technologies; (5) NovaSure endometrial ablation system, MyoSure tissue removal system, and Sonata fibroid treatment platform; and (6) QDR Bone Densitometer Systems for osteoporosis diagnosis. These products serve the continuum of women's health care from screening and diagnosis to treatment and surgical intervention. ### What are Hologic's recent innovations? Hologic's recent innovations include FDA clearance for the Genius Cervical AI algorithm for automated cervical cancer screening, the launch of Genius AI Detection 2.0 solution for enhanced breast cancer detection using deep learning algorithms, and expansion of its surgical portfolio through strategic acquisitions. The 2024 acquisition of Endomagnetics added Magseed and Magtrace technologies for breast surgery guidance, while the 2025 acquisition of Gynesonics brought the Sonata transcervical fibroid treatment system—the first FDA-cleared device combining real-time intrauterine ultrasound with radiofrequency ablation. These innovations reflect Hologic's commitment to advancing women's health through cutting-edge medical technology and artificial intelligence applications in diagnostic imaging. ## Tags b2b, healthtech, manufacturing, saas, public --- *Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*